ライフサイエンスコーパス: subcutaneous infusion

1 umumab and rHuPH20 (DARA-MD) administered by subcutaneous infusion.

2 140 every other week for 2 doses by means of subcutaneous infusion.

3 day) or placebo for 24 weeks as a continuous subcutaneous infusion.

4 Seven-day subcutaneous infusions (0.4 mug/hr) were continued.

5 113 (5 mg/kg, i.p., n=23) followed by a 24-h subcutaneous infusion (1.5 mg kg-1 h-1) by means of a mi

6 (range 95.7-727.4 mug/mL) or on day 6 after subcutaneous infusion (205.6-547.1 mug/mL).

7 s that is delivered as a 24-h/day continuous subcutaneous infusion, and we aimed to assess the safety

8 ternate routes such as rectal suppositories, subcutaneous infusions, and orally dissolvable tablets s

9 Likewise, continuous subcutaneous infusion at low (8 microg/h) or high (32 mi

10 te the same pair of compounds via continuous subcutaneous infusion from Alzet miniosmotic pumps.

11 n, a new route of bortezomib administration, subcutaneous infusion, has recently been approved.

12 dy-state conditions after 24 h of continuous subcutaneous infusion in Slco1b2(-/-) mice.

13 n analog treprostinil is also efficacious by subcutaneous infusion, is easier to administer, and has

14 ncurrent oral administration of NPS 2143 and subcutaneous infusion of 17beta-estradiol also resulted

15 hnique of tumescent liposuction involves the subcutaneous infusion of a solution containing lidocaine

16 atment of rats for 10 days with a continuous subcutaneous infusion of aldosterone also increased TSC

17 hanical stimulation in vivo before and after subcutaneous infusion of an 'inflammatory soup' (IS) wer

18 We have shown here that subcutaneous infusion of Ang II, a vasopressor known to

19 ceptor antagonism, we examined the effect of subcutaneous infusion of candesartan, a non-competitive

20 corticoid therapy replaced with a continuous subcutaneous infusion of cortisol programmed to produce

21 murine cardiac injury model was performed by subcutaneous infusion of either saline or Angiotensin II

22 re randomly assigned and received continuous subcutaneous infusion of foslevodopa-foscarbidopa plus o

23 , were randomly assigned (1:1) to continuous subcutaneous infusion of foslevodopa-foscarbidopa plus o

24 Here, a 5-day constant subcutaneous infusion of hIL-6 before portal vein insuli

25 C57BL/6 mice were treated with a continuous subcutaneous infusion of IL-2 (1 x 10(4) IU/d) plus a da

26 Subcutaneous infusion of leptin increased V(E) and HVR i

27 Here, it is shown that prolonged subcutaneous infusion of low doses of peptide by means o

28 Thus, in most cases, chronic subcutaneous infusion of low doses of rotenone does not

29 safety and efficacy of a continuous 24 h/day subcutaneous infusion of ND0612 (a levodopa-carbidopa so

30 om male rats and maintained under continuous subcutaneous infusion of obestatin.

31 at chronic inflammation induced by a 28-day, subcutaneous infusion of P. gingivalis-LPS or E. coli-LP

32 uated escalating single intravenous doses or subcutaneous infusion of PGT121.414.LS, in four groups:

33 e-release levodopa-carbidopa plus continuous subcutaneous infusion of placebo solution (n=67).

34 e-release levodopa-carbidopa plus continuous subcutaneous infusion of placebo solution.

35 studies, we showed that a 14-day continuous subcutaneous infusion of recombinant human interleukin (

36 other group (STZ + Lep) (n = 15) received a subcutaneous infusion of recombinant rat leptin (100 mic

37 iovascular safety of delivering a continuous subcutaneous infusion of the GLP-1RA exenatide (ITCA 650

38 Continuous intravenous or subcutaneous infusion of the peptide reduced the glucose

39 Mice received monthly subcutaneous infusions of cytokines while also being ass

40 FGF21-KO mice given continuous subcutaneous infusions of FGF21 for 4 weeks while on an

41 herapy were randomised 1:1 to 12 once-weekly subcutaneous infusions of rozanolixizumab 10 mg/kg or pl

42 ts were randomly assigned (1:1:1) to receive subcutaneous infusions once a week for 6 weeks of either

43 r day, or placebo administered by continuous subcutaneous infusion over 24 weeks.

44 e observed with both routes of infusion, the subcutaneous infusion produced a much greater lymphocyto

45 tion, and delivered with a Medtronic MiniMed subcutaneous infusion pump.

46 4 200 microgram/kg/d, as a continuous 14-day subcutaneous infusion, suppressed the appearance of circ

47 JB3 was delivered by subcutaneous infusion using an osmotic minipump implante

48 Intravenous and subcutaneous infusions were safe and well tolerated, wit

49 ed with recombinant methionine murine leptin subcutaneous infusion with osmotic pumps for 12-14 days